Get started today!

Good to have you back!
If you've signed in to StudyBlue with Facebook in the past, please do that again.

- StudyBlue
- Washington
- University of Washington - Seattle Campus
- Statistics
- Statistics 571
- Wakefield
- hw 7

Maziar R.

Advertisement

2009 STAT/BIOSTAT 571: Coursework 7 To be handed in by the start of the lecture on Friday 6th March, 2009. Table 1 contains pharmacokinetic data on 10 subjects who have been administered a dose of D = 30mg of the drug Cadralazine. Let Zij denote the drug concentration (in mg/ml) at time tij, j = 1,...,ni, i = 1,...,10. A one-compartment model would suggest that, in the absence of a stochastic component, the concentration at time t would be given by D V exp(?kt), where V is the volume of distribution, and k is the elimination rate. A plausible statistical model is Yij = logZij = logD ?logVi ?kitij + epsilon1ij, where epsilon1ij ?iid N(0,?2epsilon1), and Vi and ki are subject i specific volume and elimination parameters, assumed to arise from distributions with median(Vi) = V and median(ki) = k. 1. Consider marginal linear models of the form E[Yij] = ?0 + ?1tij, for j = 1,...,ni, i = 1,...,10. Give point and interval estimates for the population medians V and k, using GEE and LMEM approaches. 2. Do the assumptions required for valid inference in the previous question appear valid here? As part of this exercise you should obtain individual fits to each of the ten subjects, using the estimated random effects. 3. Suppose that we obtain data {zstar,tstar} from a new subject who has received a dose of 30mg of Cadralazine, with zstar = (z1,...,znstar)T and tstar = (t1,...,tnstar)T. Let ?star = (?star0,?star1) represent the parameters of this new subject. Using the results of the LMEM analysis construct a prior distribution for ?star, and hence derive the posterior distribution for ?star. (You may assume that ?2epsilon1 is known and equal to hatwide?2epsilon1, the estimate from the LMEM analysis.) 1 4. Suppose that the new subject provides a single log concentration zstar1 at time tstar1 = 2 hours, and that we wish to administer a further dose of size Dstar at 24 hours (by which time you may assume the previous dose has been eliminated), with the aim of attaining a concentration of 1.5mg/ml at 26 hours. Based on the previous question, provide a plot of the optimal dose Dstar versus zstar1 (with log1.0 ? zstar1 ? log2.5), explaining the method you use. 5. Now consider the nonlinear model Yij = logD ??0i ?exp(?1i)tij + epsilon1ij, with epsilon1ij ?iid N(0,?2epsilon1), and where ?i = ? ? ?0i ?1i ? ? ?iid N2 (?,D), with ? = ? ? ?0 ?1 ? ?, and D = ? ? ? 2 00 ? 2 01 ?201 ?211 ? ?, is the population distribution of ?i, i = 1,...,10. Fit this model using the nlme() software, and briefly summarize your analysis in language understandable to a non-statistician. 6. Carry out a Bayesian analysis of the previous model, using the bivariate normal prior N2 ? ? ? ? 0 0 ? ?, ? ? 10 3 0 0 103 ? ? ? ?, for?, and a Wishart prior forD?1 with r = 5 and such that the mean forD is ? ? 0.04 0 0 0.04 ? ?. Assume pi(?2epsilon1) ? ??2epsilon1 . Report the 2.5%, 50% and 97.5% points of the posterior distributions for the mode, median, and mean of the population distribution for V star, the volume of an individual randomly sampled from the population distribution. 7. Write down the population distributions of the half-life tstar1/2 = log2/kstar and the clearance Clstar = V star×kstar where tstar1/2, kstar and Clstar have analagous definitions to that of V star in the previous part. Using the results from either the nlme or Bayes analysis, estimate the probability that a subject selected from the population has a half-life greater than 3.7 hours. (You should include the nlme() and WinBUGS code in your write-up.) 2 Time point tij Subject 2 4 6 8 10 24 28 32 1 1.09 0.75 0.53 0.34 0.23 0.02 2 2.03 1.28 1.20 1.02 0.83 0.28 3 1.44 1.30 0.95 0.68 0.52 0.06 4 1.55 0.96 0.80 0.62 0.46 0.08 5 1.35 0.78 0.50 0.33 0.18 0.02 6 1.08 0.59 0.37 0.23 0.17 7 1.32 0.74 0.46 0.28 0.27 0.03 0.02 8 1.63 1.01 0.73 0.55 0.41 0.01 0.06 0.02 9 1.26 0.73 0.40 0.30 0.21 10 1.30 0.70 0.40 0.25 0.14 Table 1: Pharmacokinetic concentration data, following administration of the drug Cadralazine. 3

Advertisement

"StudyBlue is great for studying. I love the study guides, flashcards and quizzes. So extremely helpful for all of my classes!"

Alice , Arizona State University"I'm a student using StudyBlue, and I can 100% say that it helps me so much. Study materials for almost every subject in school are available in StudyBlue. It is so helpful for my education!"

Tim , University of Florida"StudyBlue provides way more features than other studying apps, and thus allows me to learn very quickly!Â I actually feel much more comfortable taking my exams after I study with this app. It's amazing!"

Jennifer , Rutgers University"I love flashcards but carrying around physical flashcards is cumbersome and simply outdated. StudyBlue is exactly what I was looking for!"

Justin , LSU
StudyBlue is not sponsored or endorsed by any college, university, or instructor.

© 2016 StudyBlue Inc. All rights reserved.

© 2016 StudyBlue Inc. All rights reserved.